1
EXHIBIT 10.20(d)
INTROGEN THERAPEUTICS
000 XXXXXXXX XXXXXX, XXXXX 0000
XXXXXX, XX 00000
(000) 000-0000
Xxxxx 00, 0000
Xxxxx-Xxxxxxx Xxxxx Pharmaceuticals Inc.
000 Xxxxxx Xxxx
X.X. Xxx 0000
Xxxxxxxxxxxx, XX 00000-0000
Gentlemen:
This letter confirms the understanding reached by Introgen and RPR with respect
to certain issues regarding the manufacturing process for Ad5CMVp-53 (the "p53
Product"). In particular, the parties agree as follows:
1. Introgen will [*] for the purpose of supplying the p53 Product materials
for clinical trials. Accordingly, until [*].
2. Notwithstanding the provisions of Paragraph 1, above, in the event that
[*].
3. [*]
[*] Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been
requested with respect to the omitted portions.
2
Xxxxx-Xxxxxxx Xxxxx Pharmaceuticals Inc.
April 19, 1999
Page 2
4. RPR represents and warrants that, other than the patent(s) and patent
applications(s) listed on Exhibit A hereto, neither RPR nor its Affiliates
has rights to any patent or patent application (including without
limitation any invention disclosure or draft patent application for which a
patent application is intended to be filed) the rights under which would be
required to carryout the [*]. Introgen represents and warrants that,
other than the patent(s) and patent applications(s) listed on Exhibit
C hereto, Introgen does not have rights to any patent or patent application
(including without limitation any invention disclosure or draft patent
application for which a patent application is intended to be filed) the
rights under which would be required to carryout the [*]. To the
extent that Exhibits A and C are not completed as of the date hereof,
the parties will complete and exchange such Exhibits within 30 days and the
same shall be initialed by the parties and attached hereto.
5. Nothing in this Letter Agreement is intended to modify the terms of the
Collaboration Agreement or the Agreement Memorandum, except as expressly
provided in and subject to Paragraph 2 above.
If RPR agrees with these terms and conditions, please execute in the spaces
provided below, and return a signed copy to me at your earliest convenience.
Best Regards,
/s/ Xxxxx X. Xxxxx
Xxxxx X. Xxxxx
Chief Executive Officer
AGREED AND ACCEPTED:
XXXXX-XXXXXXX XXXXX PHARMACEUTICALS INC.
By: [ILLEGIBLE]
-----------------------------
Title: VP
--------------------------
Date: 4/21/99
---------------------------
cc: Xxxxxx Xxxxxx, RPR
Xxx Xxxxx, WSGR
[*] Certain information on this page has been omitted and filed
separately with the Commission. Confidential treatment has been
requested with respect to the omitted portions.
